News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results for Its Beclomethasone Dipropionate HFA Product
SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The study was a Phase I open label, randomized, single-dose,
Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results for Its Beclomethasone Dipropionate HFA Product
SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The study was a Phase I open label, randomized, single-dose,
Toggle Summary Adamis Pharmaceuticals Receives Notice of Allowance for US and Japanese Patents for Its Dry Powder Inhaler
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
Adamis Pharmaceuticals Receives Notice of Allowance for US and Japanese Patents for Its Dry Powder Inhaler
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Jan 09, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Jan 09, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan 08, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan 08, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Toggle Summary Adamis Pharmaceuticals To Present at Two Upcoming Conferences
SAN DIEGO, Dec 02, 2014 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  today announced that the Company is scheduled to present a company overview at two upcoming conferences. Event: 7th Annual LD Micro Conference Date: Wednesday, December 3, 2014
Adamis Pharmaceuticals To Present at Two Upcoming Conferences
SAN DIEGO, Dec 02, 2014 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  today announced that the Company is scheduled to present a company overview at two upcoming conferences. Event: 7th Annual LD Micro Conference Date: Wednesday, December 3, 2014
Toggle Summary Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
SAN DIEGO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a
Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
SAN DIEGO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a
Toggle Summary Adamis Pharmaceuticals Announces Appointment of New Members to its Board of Directors
SAN DIEGO, CA--(Marketwired - Aug 26, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Dr. Dennis J.
Adamis Pharmaceuticals Announces Appointment of New Members to its Board of Directors
SAN DIEGO, CA--(Marketwired - Aug 26, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Dr. Dennis J.
Toggle Summary Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Aug 19, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare
Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Aug 19, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare
Toggle Summary FDA Accepts for Review Adamis’ New Drug Application for Its Epinephrine Pre-Filled Syringe
SAN DIEGO, CA--(Marketwired - Jul 29, 2014) -    Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg
FDA Accepts for Review Adamis’ New Drug Application for Its Epinephrine Pre-Filled Syringe
SAN DIEGO, CA--(Marketwired - Jul 29, 2014) -    Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg
Toggle Summary Adamis Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
SAN DIEGO, CA--(Marketwired - Jun 6, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced that it will present at the 9 th  Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr.
Adamis Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
SAN DIEGO, CA--(Marketwired - Jun 6, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced that it will present at the 9 th  Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr.
Toggle Summary Adamis CEO Dr. Dennis J. Carlo to Present at the LD Micro Invitational
SAN DIEGO, CA -- (Marketwired) -- 06/04/14 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr.
Adamis CEO Dr. Dennis J. Carlo to Present at the LD Micro Invitational
SAN DIEGO, CA -- (Marketwired) -- 06/04/14 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr.
Toggle Summary Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled Syringe
SAN DIEGO, CA--(Marketwired - May 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe (PFS) product.
Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled Syringe
SAN DIEGO, CA--(Marketwired - May 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe (PFS) product.
Toggle Summary Adamis Receives Notice of Key Allowance for US Patent That Supports Its Cancer Immunology Portfolio
SAN DIEGO, CA--(Marketwired - Jan 24, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States.
Adamis Receives Notice of Key Allowance for US Patent That Supports Its Cancer Immunology Portfolio
SAN DIEGO, CA--(Marketwired - Jan 24, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States.
Toggle Summary Adamis Pharmaceuticals Announces Full Exercise of Underwriter's Over-Allotment Option
SAN DIEGO, CA--(Marketwired - Jan 13, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share
Adamis Pharmaceuticals Announces Full Exercise of Underwriter's Over-Allotment Option
SAN DIEGO, CA--(Marketwired - Jan 13, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share
Toggle Summary Adamis Pharmaceuticals Announces Completion of Acquisition
SAN DIEGO, CA--(Marketwired - Jan 7, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual
Adamis Pharmaceuticals Announces Completion of Acquisition
SAN DIEGO, CA--(Marketwired - Jan 7, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
San Diego, California - December 18, 2013  - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share.
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
San Diego, California - December 18, 2013  - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share.
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse Stock Split
SAN DIEGO, CA--(Marketwired - Dec 13, 2013) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are
Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse Stock Split
SAN DIEGO, CA--(Marketwired - Dec 13, 2013) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering
SAN DIEGO, CA--(Marketwired - Nov 20, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants.
Adamis Pharmaceuticals Announces Proposed Public Offering
SAN DIEGO, CA--(Marketwired - Nov 20, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants.
Toggle Summary Adamis Announces Positive Results of Study Concerning C31G in Treating Herpes Simplex Virus (HSV) Eye Infection
SAN DIEGO, CA--(Marketwired - Sep 9, 2013) -   Adamis Pharmaceuticals Corporation ( OTCQB :   ADMP ) today announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes
Adamis Announces Positive Results of Study Concerning C31G in Treating Herpes Simplex Virus (HSV) Eye Infection
SAN DIEGO, CA--(Marketwired - Sep 9, 2013) -   Adamis Pharmaceuticals Corporation ( OTCQB :   ADMP ) today announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes
Toggle Summary Adamis Prostate Cancer Drug Receives Allowance for Patent in USA
SAN DIEGO, CA--(Marketwired - Aug 21, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology
Adamis Prostate Cancer Drug Receives Allowance for Patent in USA
SAN DIEGO, CA--(Marketwired - Aug 21, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology
Toggle Summary Adamis Pharmaceuticals Announces Investor Update Conference Call
SAN DIEGO, CA--(Marketwired - Aug 9, 2013) - Adamis Pharmaceuticals Corp. ( OTCQB :  ADMP ) ("the Company"), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
Adamis Pharmaceuticals Announces Investor Update Conference Call
SAN DIEGO, CA--(Marketwired - Aug 9, 2013) - Adamis Pharmaceuticals Corp. ( OTCQB :  ADMP ) ("the Company"), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
Toggle Summary Adamis Pharmaceuticals Signs Agreement to Acquire Dry Powder Inhaler Technology From 3M Company
SAN DIEGO, CA--(Marketwired - Aug 6, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Company's ( NYSE : MMM ) Taper Dry Powder Inhaler (DPI) technology under
Adamis Pharmaceuticals Signs Agreement to Acquire Dry Powder Inhaler Technology From 3M Company
SAN DIEGO, CA--(Marketwired - Aug 6, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Company's ( NYSE : MMM ) Taper Dry Powder Inhaler (DPI) technology under
Toggle Summary Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Jul 1, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued senior secured convertible promissory notes and warrants to purchase up to 13,004,316 shares
Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Jul 1, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued senior secured convertible promissory notes and warrants to purchase up to 13,004,316 shares
Toggle Summary Adamis Pharmaceuticals CEO Provides Update for Shareholders
SAN DIEGO ,  May 3, 2013  /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology
Adamis Pharmaceuticals CEO Provides Update for Shareholders
SAN DIEGO ,  May 3, 2013  /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology